Gemin X Pharmaceuticals to Present Data on Obatoclax at American Society of Hematology Annual MeetingMALVERN, Pa. & MONTREAL, QC--(BUSINESS WIRE)--Dec 3, 2007 - Gemin X announced today that results of several clinical and preclinical studies of its lead anti-cancer candidate obatoclax (GX15-070) will be presented at the 49th annual meeting of the American Society of Hematology (ASH) in Atlanta, GA. Obatoclax is a novel, small molecule candidate in Phase 2 trials in multiple cancer indications that is specifically designed to inhibit all relevant members of the Bcl-2 protein family, a validated cancer target, restoring the natural cell death process of apoptosis.
"The presentation of multiple abstracts at ASH demonstrates the therapeutic promise of obatoclax and provides us with additional important information on the compound that will support its extensive clinical development program," said Dr. Gordon Shore, Chief Scientific Officer and Interim Chief Executive Officer of Gemin X. "These abstracts underscore obatoclax's potential synergistic effects in combination with other treatments, its utility in indications resistant to current therapies, its ability to initiate apoptosis, and its activity in a variety of cancer types. We believe that this emerging positive profile may position obatoclax as a potential new therapeutic that may improve treatment outcomes for cancer patients."
Details on the abstractsbeing presented at ASH: Abstract Title: Direct and Enhanced Cytotoxicity of the Bcl-2 Family Inhibitor GX15-070 on Rituximab- Sensitive and Rituximab-Resistant B-NHL Clones. Abstract No. 1402 Poster Session Info: Lymphoma: Pre-Clinical: Chemotherapy and Biologic Agents I, Board # 556-I Saturday, December 8 5:30 PM Abstract Title: Bcl-2 Phosphorylation Modulates Sensitivity to the BH3-Mimetic GX15-070 (Obatoclax) and Reduces its Synergistic Interaction with Bortezomib in Chronic Lymphocytic Leukemia Cells. Abstract No. 3464 Poster Session Info: Molecular Response Determinants, Board # 683-III Monday, December 10 5:00 PM Abstract Title: GX15-070 and Bortezomib Induce Up-Regulation of BH3 Single Domain Pro-Apoptotic Proteins Puma and Noxa and is Associated with Synergistic Anti-Tumor Activity in Rituximab-Sensitive, Rituximab-Resistant Cell Lines (RSCL and RRCL), and Primary Lymphoma Patient Specimens. Abstract No. 1389 Poster Session Info: Lymphoma: Pre-Clinical: Chemotherapy and Biologic Agents I, Board # 543-I Saturday, December 8 5:30 PM Abstract Title: Targeting 14-3-3 Sensitizes Native and Mutant BCR-ABL to Inhibition with U0126, Rapamycin and Bcl-2 Inhibitor GX15-070. Abstract No. 2920 Poster Session Info: Chronic Myeloid Leukemia: Biology and Pathophysiology II, Board #139-III Monday, December 10 5:00 PM Abstract Title: A Phase 1 Trial of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate (GX15-070) in Combination with Bortezomib in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Abstract No. 2569 Poster Session Info: New Agents and Treatment Approaches in Non- Hodgkin Lymphoma, Board #759-II Sunday, December 9 6:00 PM Abstract Title: A Phase II Trial of the Small Molecule Pan-Bcl-2 Family Inhibitor Obatoclax Mesylate (GX15-070) Administered by a 24-h Continuous Infusion Every 2 Weeks to Patients with Chronic Idiopathic Myelofibrosis (CIMF). Abstract No. 3553 Poster Session Info: Myeloproliferative Syndromes: Therapy, Board #772-III Monday, December 10 5:00 PM Abstract Title: A Phase I Trial of the Small Molecule Pan-Bcl-2 Family Inhibitor Obatoclax Mesylate (GX15-070) Administered by Continuous Infusion for up to Four Days to Patients with Hematological Malignancies. Abstract No. 892 Poster Session Info: Acute Myeloid Leukemias: Therapy, Excluding Transplantation I, Board #46-I Saturday, December 8 5:30 PM Abstract Title: The BH3-Mimetic Obatoclax Restores the Response to Dexamethasone in Glucocorticoid-Resistant ALL through Induction of Autophagy. Abstract No.806 Oral Session Info: Simultaneous Session: Molecular Pharmacology: Drug Resistance , Tuesday, December 11 7:45 AM
Obatoclax (GX15-070) is a small molecule indole bipyrrole drug compound that was discovered and is being developed at Gemin X. The attractive safety profile and mechanism of action of obatoclax offers the opportunity to treat many forms of cancer as both a single agent and in combination with current treatments. Obatoclax is currently being assessed in multiple Phase 2 company-sponsored clinical trials directed against multiple solid tumor and hematologic malignancies. In addition to clinical activity in multiple indications, obatoclax is generally well tolerated, and is without evidence of immuno- and myelosuppression.
About Gemin X
Gemin X Pharmaceuticals, Inc., through its subsidiary Gemin X Biotechnologies Inc., specializes in the discovery and development of target-based novel cancer therapeutics. Gemin X's lead product, obatoclax (GX15-070), is a small molecule, pan-inhibitor of Bcl-2 proteins and is currently in Phase 2 clinical trials. Gemin X is also developing GMX1777, a small molecule that targets cancer metabolism by a p53-independent mechanism. Gemin X is privately held and is located in Malvern, Pennsylvania and Montreal, Quebec. For additional information please visit Gemin X at www.geminx.com.
MacDougall Biomedical Communications
Jennifer Greenleaf, 508-647-0209
Gemin X Biotechnologies Inc.
Diane Viens, 514-281-8989 ext.387
Posted: December 2007